Clenbuterol 40 mcg

Clenbuterol 40 mcg contains clenbuterol hydrochloride, a beta-2 adrenergic agonist. In the United States, it is approved only for veterinary use in horses with respiratory conditions. In non-medical bodybuilding contexts, it is widely used off-label for its thermogenic and lipolytic effects to accelerate fat loss.

In clinical contexts where clenbuterol is approved for human use, therapeutic dosing is typically 20 mcg twice daily. In non-medical contexts, it is typically referenced as being taken in split doses, with daily intakes of 120–200 mcg frequently reported.

Clenbuterol is a beta-2 adrenergic agonist that provides bronchodilating properties with minimum effect on the cardiovascular system at therapeutic doses. Animal studies have shown that it stimulates muscle beta-adrenoceptors to induce hypertrophy, increasing muscle mass and protein synthesis rates. It also has thermogenic and lipolytic effects.

Following oral administration, clenbuterol plasma levels reach maximum values within 2.5 hours and last for over 6 hours. When administered repeatedly twice daily, plasma levels reach a plateau within 4 days.

The half-life of clenbuterol in plasma was estimated to be about 35 hours in human volunteers. This long half-life supports less frequent dosing compared to shorter-acting beta-2 agonists.

No. In the United States, clenbuterol is not approved by the FDA for human use and is restricted to veterinary medicine. In parts of Europe and Latin America, it is approved as a bronchodilator for human use.

Clenbuterol displays greater selectivity and potency, in addition to a significantly different pharmacokinetic profile, including greater oral bioavailability and a longer half-life compared to albuterol. Both are beta-2 agonists, but clenbuterol's longer duration of action distinguishes it.

Clenbuterol is a beta-2 adrenergic agonist that stimulates lipolysis through adrenergic receptors. T3 (triiodothyronine) is a thyroid hormone that increases metabolic rate through thyroid hormone receptors. Both are referenced in non-medical fat-loss contexts, and some protocols combine them, though this increases cardiovascular and metabolic risks.

Clinical therapeutic dosing where approved is typically 20 mcg twice daily. A 40 mcg tablet is therefore a moderate single dose. In non-medical contexts, users often take multiple tablets to reach daily intakes of 120–200 mcg. Clenbuterol 40 mcg is labeled at 40 mcg per tablet.

Clenbuterol 40 mcg is labeled at 40 micrograms of clenbuterol hydrochloride per tablet. It is supplied in a 100-tablet package, giving 4,000 mcg of total labeled clenbuterol content.

Yes. A published laboratory report dated August 31, 2024 measured Clenbuterol 40 mcg at 39.56 mcg per tablet, equivalent to 98.90% of its 40 mcg label claim. Complete reports can be viewed in the Lab Reports tab.

Yes. Clenbuterol use is associated with cardiovascular complications including tachycardia, palpitations, hypertension, arrhythmias, and myocardial hypertrophy. A study in horses demonstrated that chronic clenbuterol administration resulted in significantly increased left ventricular internal dimensions and wall thickness, suggesting negative alterations in cardiac function. Another study in mice showed that repeated doses of clenbuterol resulted in a marked increase in heart muscle weight.